Cheryl R Blanchard Anika Therapeutics, Inc. (ANIK) insider trading activity

Cheryl R Blanchard is President, CEO, Director of Anika Therapeutics, Inc.. Currently has a direct ownership of 197,320 shares of ANIK, which is worth approximately $2.18 Million. The most recent transaction as insider was on Mar 17, 2025, when has been sold 12,152 shares (Common Stock) at a price of $15.91 per share, resulting in proceeds of $193,338. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 197K

0% 3M change

30.08% 12M change

Total Value Held $2.18 Million

Cheryl R Blanchard Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 17 2025	SELL Payment of exercise price or tax liability	$193,338 $15.91 p/Share	12,152 Reduced 5.8%	197,320 Common Stock
Mar 17 2025	BUY Exercise of conversion of derivative security	-	25,132 Added 10.71%	209,472 Common Stock
Mar 11 2025	SELL Payment of exercise price or tax liability	$212,813 $16.79 p/Share	12,675 Reduced 6.43%	184,340 Common Stock
Mar 11 2025	BUY Exercise of conversion of derivative security	-	30,060 Added 13.24%	197,015 Common Stock
Mar 10 2025	SELL Payment of exercise price or tax liability	$97,576 $16.62 p/Share	5,871 Reduced 3.4%	166,955 Common Stock
Mar 10 2025	BUY Exercise of conversion of derivative security	-	20,002 Added 10.37%	172,826 Common Stock
Mar 11 2024	SELL Payment of exercise price or tax liability	$714,609 $25.54 p/Share	27,980 Reduced 15.57%	151,694 Common Stock
Mar 11 2024	BUY Exercise of conversion of derivative security	-	64,480 Added 27.95%	166,228 Common Stock
Apr 26 2023	SELL Payment of exercise price or tax liability	$287,106 $26.34 p/Share	10,900 Reduced 8.71%	114,255 Common Stock
Apr 26 2023	BUY Exercise of conversion of derivative security	-	24,575 Added 16.41%	125,155 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$344,807 $26.1 p/Share	13,211 Reduced 11.61%	100,580 Common Stock
Mar 10 2023	BUY Exercise of conversion of derivative security	-	30,060 Added 20.9%	113,791 Common Stock
Mar 09 2023	SELL Payment of exercise price or tax liability	$113,883 $26.91 p/Share	4,232 Reduced 4.81%	83,731 Common Stock
Mar 09 2023	BUY Exercise of conversion of derivative security	-	14,419 Added 14.08%	87,963 Common Stock
Apr 26 2022	BUY Exercise of conversion of derivative security	-	24,576 Added 25.23%	72,826 Common Stock
Mar 11 2022	BUY Open market or private purchase	$207,279 $25.59 p/Share	8,100 Added 11.9%	59,992 Common Stock
Mar 09 2022	BUY Exercise of conversion of derivative security	-	14,420 Added 21.75%	51,892 Common Stock
Jun 15 2021	BUY Exercise of conversion of derivative security	$100,000 $33.4 p/Share	2,994 Added 7.4%	37,472 Common Stock
Apr 26 2021	BUY Exercise of conversion of derivative security	-	24,575 Added 41.62%	34,478 Common Stock

Also insider at

DARE

Dare Bioscience, Inc. Healthcare

Director

VIGL

Vigil Neuroscience, Inc. Healthcare

CRB